CompletedPhase 3NCT04195906

Phase 3 Study of SNF472 for Calciphylaxis

Studying Calciphylaxis

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sanifit Therapeutics S. A.
Principal Investigator: Alex Gold, MD
Sanifit Therapeutics
Intervention: Experimental: SNF472(drug)
Enrollment: 71 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2022

Study locations (30)

AKDHC Medical Research Services, Phoenix, Arizona, United States
California Institute of Renal Research, El Centro, California, United States
California Institute of Renal Research, Escondido, California, United States
Kidney Disease Medical Group, Glendale, California, United States
DaVita Clinical Research, Lynwood, California, United States
Apex Research of Riverside, Riverside, California, United States
Fresenius Kidney Care, San Diego, California, United States
North America Research Institute, San Dimas, California, United States
Amicis Research Center, Vacaville, California, United States
Colorado Kidney Care, Denver, Colorado, United States
Boca Nephrology, PA, Boca Raton, Florida, United States
DaVita Clinical Research, Hollywood, Florida, United States
Novel Outcomes Research, Spring Hill, Florida, United States
DaVita Clinical Research, Tampa, Florida, United States
Fresenius Kidney Care, Tampa, Florida, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04195906 on ClinicalTrials.gov

Other trials for Calciphylaxis

Additional recruiting or active studies for the same condition.

See all trials for Calciphylaxis →

← Back to all trials